Tirzepatide, the first dual agonist approved for T2D and obesity management, acts on both GLP‐1 and GIP receptors and can lead to 15.6%–20.9% mean weight loss after 72 weeks of treatment [12, 13]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.